JCI Insight Submission Guide: What to Prepare Before You Submit
A practical JCI Insight submission guide for authors deciding whether the manuscript is broad, disease-relevant, category-ready, and complete enough for the journal's editorial screen.
Readiness scan
Find out if this manuscript is ready to submit.
Run the Free Readiness Scan before you submit. Catch the issues editors reject on first read.
How to approach JCI Insight
Use the submission guide like a working checklist. The goal is to make fit, package completeness, and cover-letter framing obvious before you open the portal.
Stage | What to check |
|---|---|
1. Scope | Define the disease-facing scientific question |
2. Package | Check that the mechanistic chain supports the translational framing |
3. Cover letter | Tighten the abstract around human relevance and consequence |
4. Final check | Position the paper honestly relative to JCI and other translational flags |
Quick answer: This JCI Insight submission guide is for manuscripts that need to prove broad biomedical relevance before review.
Submit when the abstract, category choice, title page, figures, methods, human or disease evidence, references, data availability, and cover letter show a coherent biology or disease contribution for JCI Insight's physician-scientist readership.
Across our JCI Insight pre-submission reviews, the work that clears the desk delivers mechanistic, often translational insight into biology or disease with rigorous support, while the work that stalls is sound but its mechanism or biomedical relevance is thin. JCI Insight sits at the biology-medicine interface with a focus on technically rigorous studies, so reviewers expect both real mechanism and clear relevance. Submit if your study advances disease-relevant biology with solid mechanistic support; think twice if the mechanism is incomplete or the disease link is loose.
Run a JCI Insight pre-submission readiness check before upload, or use the checks below manually.
For a fast first pass on translational and readership fit, run the Manusights readiness review. In practice, editors specifically screen for abstract, methods, figure, cover letter, and reference-list signals before full review.
Use this guide when the decision is whether a manuscript should enter the JCI Insight process now or be redirected to JCI, Clinical and Translational Medicine, Science Translational Medicine, eLife, Nature Communications, The American Journal of Pathology, or a specialty clinical journal first. For baseline journal context, see the JCI Insight journal profile.
Verify the current editorial leadership on the journal's editorial-team page before quoting any name in a cover letter.
We see the same pattern in manuscript-specific diagnostics: a biomedical paper can have solid data and still miss JCI Insight if the first read feels like a subspecialty article that has not made its broader disease or biology consequence load-bearing.
From our manuscript review practice
For JCI Insight, the first-read question is whether the manuscript advances biology or disease understanding for a broad physician-scientist audience, not whether it merely includes a disease model.
What is the real JCI Insight submission decision?
JCI Insight states that Research manuscripts report new insights into biology and disease using preclinical models as well as materials and data derived from humans. The same guidance says these manuscripts should be scientifically important and of broad interest to the JCI Insight readership. Clinical Research and Public Health papers, Resource and Technical Advance papers, Research Letters, and Physician-Scientist Development pieces carry different constraints and expectations.
That means the first submission decision is not only category selection. The real decision is whether the manuscript's abstract, first figures, methods, human or disease relevance, and cover letter make the breadth obvious. A disease model alone is not enough. A cohort alone is not enough. A technically strong tool is not enough unless the biological or disease insight is visible.
What official requirements matter before upload?
Requirement | Source fact | Submission implication |
|---|---|---|
Core categories | Research, Clinical Research and Public Health, Resource and Technical Advance, Research Letter, Physician-Scientist Development | Choose the lane before writing the pitch |
Research manuscript length | Recommended 9,000 words, maximum 12,000 words inclusive of title page, text, references, legends, and tables | Do not hide a sprawling argument behind a broad journal target |
Abstract | Research submissions use a 200-word abstract limit | The disease or biology advance must be visible quickly |
Research Letter | 1,200 words and 1 display item | Use the short lane only for a focused finding |
APC | $5,000 listed for non-ASCI-member full research categories | Confirm funding and article type before acceptance |
This guide tells you what JCI Insight editors look for in physician-scientist readership fit; the review tells you whether your paper passes that screen through the abstract, category choice, human evidence, methods, figures, and cover letter before upload. Manusights reviews 1,000+ manuscripts and reports, we do not train models on your manuscript text, and the translational-fit review includes a 60-day money-back guarantee when the deliverable is not met.
JCI Insight editorial triage timeline
This timeline translates the public JCI Insight first-submission instructions into a readiness sequence. It should be treated as a preparation map rather than a guaranteed decision schedule.
Day 0: submit through the JCI family submission site at JCI submission portal or choose the Dual-Journal Submission option when the JCI/JCI Insight routing decision is still live. Before upload, confirm the PDF, matching Word or RTF text file, supplemental files, supporting data values, author contributions, conflict-of-interest statement, funding support, statistics paragraph, study approval language, and data availability paragraph.
Day 1 to 3: staff and file checks can expose mismatches between the PDF and source text, missing supplemental material, unclear author contributions, absent conflicts language, incomplete supporting-data values, or category mismatch. These are preventable first-submission problems, not scientific disagreements.
Day 4 to 10: the editor-facing read usually tests whether the category and evidence density fit JCI Insight. Research and Resource manuscripts need broad biology or disease insight; Clinical Research and Public Health papers need human-participant or population findings that inform disease pathogenesis, therapeutics, diagnosis, prevention, or implementation.
Day 11: if the paper is plausible, the decision shifts toward academic-editor and reviewer fit; if it is not, the authors should revise the category, strengthen the human or disease relevance, or route to JCI, Clinical and Translational Medicine, Science Translational Medicine, The American Journal of Pathology, eLife, Nature Communications, or a specialty clinical journal.
Before Day 0, audit the required artifacts as a checklist: cover letter, data availability statement, ethics approval or study approval, conflicts of interest, author contributions, funding support, supporting data values, supplemental files, potential reviewers, excluded reviewers, and figure files.
Source limitations: official Jci Insight journal and publisher pages define scope, article types, and submission mechanics, but they do not publish manuscript-level desk decisions for Jci Insight; the patterns below combine public guidance, recent issue review, and anonymized Manusights pre-submission review work for this journal family.
Of the JCI Insight papers we pre-screen, the recurring desk-screen patterns
Across Manusights submission reviews for biomedical, translational, preclinical, clinical, cohort, resource, disease-model, immunology, oncology, metabolism, infection, neuroscience, and public-health manuscripts targeting JCI Insight, the recurring issue is not whether the work is real. It is whether the manuscript components make a broad physician-scientist case before the editor loses the thread.
The mechanism is interesting but the disease consequence arrives late
For manuscripts targeting JCI Insight, this pattern appears when the abstract and Figure 1 read like a mechanism paper while the human or disease relevance appears only near the end. JCI Insight can publish preclinical work, but its readership still expects biology and disease relevance to work together. A token cohort, patient sample, clinical table, or final validation panel rarely rescues a manuscript whose real center of gravity is a narrow molecular story.
The manuscript components to test are the abstract, first figure sequence, methods, patient or model description, statistical plan, disease-relevance paragraph, and cover letter. The abstract should name the biological or disease question, not only the pathway. Figure 1 should orient a physician-scientist reader before narrow mechanistic detail takes over. Methods should describe human materials, animal models, cell systems, approvals, statistics, and reproducibility in enough detail for cross-specialty review. The cover letter should explain why JCI Insight is a better target than a specialty biology or disease journal.
Nearby routing matters. If the mechanism is strong but disease relevance is secondary, eLife, The EMBO Journal, Cell Reports, or a specialty mechanistic journal may be cleaner. If the work is clinically important but mechanistically light, a disease-specific clinical journal may fit better. JCI Insight remains credible when mechanism and disease consequence support the same claim.
Check whether your JCI Insight disease relevance is load-bearing →
Human evidence is present but not integrated into the argument
For manuscripts targeting JCI Insight, the second pattern appears when a manuscript contains human samples, patient data, public-health data, clinical metadata, or translational validation, but the human evidence is not doing real argumentative work. Editors and reviewers need to see how the human component changes confidence in the biology, disease mechanism, diagnosis, treatment implication, prevention claim, or public-health interpretation.
The component-level check is specific. The methods should define cohort construction, inclusion and exclusion criteria, approvals, sample handling, assay timing, missing-data handling, statistics, and confounder logic where relevant. Tables should make the study population readable. Figures should connect human evidence to the mechanistic or clinical claim rather than placing it as an isolated validation. The discussion should describe limits honestly, especially when human data are small, retrospective, exploratory, or from a narrow population.
This pattern often means the paper belongs elsewhere for now. A narrow clinical observation may fit a specialty journal. A resource paper may need stronger biological insight before JCI Insight. A public-health analysis may fit a field-specific venue if the physician-scientist readership case is not broad. JCI Insight should remain the target when the human component is central to the paper's importance.
Check whether your JCI Insight human evidence is integrated →
Category choice makes the manuscript look thinner than it is
For manuscripts targeting JCI Insight, the third failure pattern is category mismatch. Authors sometimes force a short high-interest observation into a full Research frame, present a resource without enough biological insight, or treat Clinical Research and Public Health as a home for any human dataset. The result is a submission that feels incoherent even when the underlying study is useful.
The manuscript components to review are the title page, abstract, main text length, figure count, display-item logic, methods, data-availability statement, and cover letter. A Research manuscript should have enough breadth and evidence to justify the full frame. A Research Letter should be sharply focused and built around one display item. A Resource and Technical Advance paper should show why the tool, dataset, or model advances the status quo and yields biological insight. A Clinical Research and Public Health paper should make the human-participant or population contribution central.
If the category is wrong, the editor may read incompleteness where the real problem is packaging. Compare honestly with JCI, Clinical and Translational Medicine, Science Translational Medicine, Nature Communications, The American Journal of Pathology, and specialty clinical journals before uploading. JCI Insight works best when the category and evidence density match.
Check whether your JCI Insight article category matches the manuscript →
How should JCI Insight be compared with nearby journals?
Venue | Better fit when | Think twice when | Editorial pressure |
|---|---|---|---|
JCI Insight | Mechanism and disease relevance matter to a broad physician-scientist readership | The readership case is local to one subspecialty | Biology or disease insight |
JCI | Priority, breadth, and evidence density are stronger than the JCI Insight route | The manuscript is good but not flagship-level | High-priority medicine-facing advance |
Clinical and Translational Medicine | Translational or clinical mechanism is broad and open-access fit matters | The study is too narrow or underpowered | Translational evidence chain |
Science Translational Medicine | Translational advance is very high priority with strong mechanistic and clinical relevance | The paper is solid but not field-shifting | Practice-changing translational claim |
Specialty clinical journal | Disease-specific practice community is the primary reader | The paper needs a broader biomedical audience | Specialty clinical usefulness |
Should you submit now?
Readiness check
Run the scan against the requirements while they're in front of you.
See score, top issues, and journal-fit signals before you submit.
Submit If
- the abstract names the biology or disease advance in language a physician-scientist outside the subspecialty can follow
- the first figures make mechanism and disease relevance visible early
- human, model, cohort, or public-health evidence is central rather than decorative
- the article category matches the evidence density and display-item logic
- the cover letter explains why JCI Insight is better than JCI, a specialty clinical journal, or a mechanistic biology venue
Think Twice If
- the disease relevance arrives only in the last result or discussion section
- human samples are used as a token validation rather than a core part of the argument
- the manuscript is too narrow for a cross-specialty physician-scientist reader
- the chosen category makes the paper look incomplete
- the methods or figures would require major clarification before outside review
Final checklist before submission
- Rewrite the abstract so disease or biological importance is visible within the 200-word limit.
- Confirm that the selected category matches the length, figure, and evidence shape.
- Move the decisive human, model, or disease-relevance figure into the main manuscript.
- Audit methods for approvals, cohort logic, statistics, reagents, and reproducibility details.
- Use the cover letter to explain readership fit and category fit in plain language.
Before you upload, run a JCI Insight submission readiness check to test scope, category, human relevance, figures, methods, and nearby-journal routing.
Related submission guides
Use these nearby guides when the target journal is still uncertain:
How this Jci Insight guide was checked
For the related journal overview, see Jci Insight submission guide. In our work on Jci Insight submissions, we observe that editors specifically screen the abstract, first figures, cover letter, and evidence package for whether the manuscript answers the journal's stated fit test; our analysis of Jci Insight pages treats those checks as submission-risk signals, not as official guidance.
Frequently asked questions
Submit through the JCI family submission portal after choosing the correct category and preparing a complete first-submission package. The manuscript should read as a broad biology or disease contribution for a physician-scientist audience, not as a narrow specialty report with clinical language added late.
JCI Insight considers research that reports new insights into biology and disease using preclinical models as well as materials and data derived from humans. The work should have scientific importance, broad interest, disease relevance, and category fit.
The JCI Insight open-access page lists Article Processing Charges of $5,000 for non-ASCI-member Research, Clinical Research and Public Health, and Resource and Technical Advance papers, with lower listed charges for Research Letters and qualifying groups.
Common problems include a readership case that is too narrow, human relevance that is appended instead of load-bearing, category mismatch, and figures or methods that do not let physician-scientist reviewers trust the claim.
Sources
Before you upload
Choose the next useful decision step first.
Move from this article into the next decision-support step. The scan works best once the journal and submission plan are clearer.
Use the scan once the manuscript and target journal are concrete enough to evaluate.
Anthropic Privacy Partner. Your manuscript is never used to train any model.
Where to go next
Same journal, next question
- How to Avoid Desk Rejection at JCI Insight (2026)
- JCI Insight Submission Process: What Happens After You Upload
- JCI Insight Pre Submission Checklist: 12 Items Editors Verify Before Peer Review
- JCI Insight Review Time: What Authors Can Actually Expect
- JCI Insight 'Under Review': What Each Status Means and When to Expect a Decision
- JCI Insight Acceptance Rate (2026): What the ~30% Number Actually Means